- Home
- LBRX vs SPFI Comparison
LBRX vs SPFI Comparison
Compare LBRX & SPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LBRX | SPFI |
|---|---|---|
| Founded | 2015 | 1941 |
| Country | United States | United States |
| Employees | N/A | 600 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.2M | 632.4M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LBRX | SPFI |
|---|---|---|
| Price | $19.89 | $38.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $49.00 | $41.75 |
| AVG Volume (30 Days) | ★ 531.1K | 61.5K |
| Earning Date | 02-15-2026 | 01-23-2026 |
| Dividend Yield | N/A | ★ 1.65% |
| EPS Growth | N/A | ★ 36.91 |
| EPS | N/A | ★ 3.51 |
| Revenue | N/A | ★ $205,251,000.00 |
| Revenue This Year | N/A | $13.88 |
| Revenue Next Year | N/A | $13.05 |
| P/E Ratio | ★ N/A | $11.09 |
| Revenue Growth | N/A | ★ 11.60 |
| 52 Week Low | $13.36 | $30.01 |
| 52 Week High | $23.15 | $42.38 |
Technical Indicators
Market Signals| Indicator | LBRX | SPFI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.90 |
| Support Level | N/A | $38.03 |
| Resistance Level | N/A | $39.47 |
| Average True Range (ATR) | 0.00 | 0.92 |
| MACD | 0.00 | -0.27 |
| Stochastic Oscillator | 0.00 | 17.87 |
Price Performance
Historical ComparisonAbout LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.